Staff editor
Topical treatment is achieving all endpoints for efficacy and safety in mild, moderate, and severe atopic dermatitis.
Amine Zorgani (Microbiome Mavericks) talks about the importance of the skin microbiome in maintaining skin health and the need for continued research in this field.
The collaboration will focus on various aspects of the human microbiome that could benefit new product development.
Elisabetta Caselli, University of Ferrara (Italy), talks about a new and innovative use of probiotics to modulate the "hospital microbiome” in order to reduce the use of chemical disinfectants.
George Paraskevakos, Executive Director at International Probiotics Association, talks about probiotic and live biotherapeutic products market evolution and perspective.
The highlights of the Postbiotics Discussion Panel that took place in Bratislava during IPC 2023.
The FDA has granted orphan drug designation for IBT’s product IBP-1016 for gastroschisis.
Philippe Langella, Research Director at the French National Institute of Agricultural Research, discussed the potential of Faecalibacterium Prausnitzii as Live Biotherapeutics for several disease.
The transaction represents an enterprise value of €275 million, an estimated 2023 EV/EBITDA multiple of 18x.
MAP 315, is a novel live biotherapeutic product being developed for the treatment of ulcerative colitis and was discovered and developed using Microba’s data-driven Therapeutics Platform.
